215 related articles for article (PubMed ID: 8297720)
1. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
Los G; van Vugt MJ; Pinedo HM
Br J Cancer; 1994 Feb; 69(2):235-41. PubMed ID: 8297720
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.
Los G; Tuyt L; van Vugt M; Schornagel J; Pinedo HM
Cancer Chemother Pharmacol; 1993; 32(6):425-33. PubMed ID: 8258189
[TBL] [Abstract][Full Text] [Related]
3. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
[TBL] [Abstract][Full Text] [Related]
4. Effect of hyperthermia on cisplatin and carboplatin disposition in the isolated, perfused tumour and skin flap.
Vaden SL; Page RL; Williams PL; Riviere JE
Int J Hyperthermia; 1994; 10(4):563-72. PubMed ID: 7963811
[TBL] [Abstract][Full Text] [Related]
5. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
Los G; van Vugt MJ; den Engelse L; Pinedo HM
Biochem Pharmacol; 1993 Oct; 46(7):1229-37. PubMed ID: 8216374
[TBL] [Abstract][Full Text] [Related]
6. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats.
Los G; Sminia P; Wondergem J; Mutsaers PH; Havemen J; ten Bokkel Huinink D; Smals O; Gonzalez-Gonzalez D; McVie JG
Eur J Cancer; 1991; 27(4):472-7. PubMed ID: 1827723
[TBL] [Abstract][Full Text] [Related]
7. Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation.
Teicher BA; Pfeffer MR; Alvarez Sotomayor E; Herman TS
Int J Hyperthermia; 1991; 7(5):773-84. PubMed ID: 1834752
[TBL] [Abstract][Full Text] [Related]
8. Interaction of cis-diamminedichloro-platinum(II) and its analogues cis-1,1- cyclobutanedicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum(II) and cis-diammine(glycolato)platinum with hyperthermia in vivo.
Takahashi I; Maehara Y; Kusumoto H; Kusumoto T; Baba H; Kohnoe S; Sugimachi K
Oncology; 1996; 53(1):68-72. PubMed ID: 8570136
[TBL] [Abstract][Full Text] [Related]
9. Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.
Vaden SL; Williams PL; Page RL; Riviere JE
Cancer Chemother Pharmacol; 1993; 32(1):31-8. PubMed ID: 8462121
[TBL] [Abstract][Full Text] [Related]
10. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action.
Los G; Verdegaal E; Noteborn HP; Ruevekamp M; de Graeff A; Meesters EW; ten Bokkel Huinink D; McVie JG
Biochem Pharmacol; 1991 Jul; 42(2):357-63. PubMed ID: 1859450
[TBL] [Abstract][Full Text] [Related]
11. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
Ohno S; Strebel FR; Stephens LC; Siddik ZH; Makino M; Klostergaard J; Tomasovic SP; Khokhar AR; Bull JM
Cancer Res; 1992 Aug; 52(15):4096-101. PubMed ID: 1638521
[TBL] [Abstract][Full Text] [Related]
12. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy and apoptosis and necrosis kinetics of doxorubicin compared with cisplatin, combined with whole-body hyperthermia in a rat mammary adenocarcinoma.
Toyota N; Strebel FR; Stephens LC; Matsuda H; Oshiro T; Jenkins GN; Bull JM
Int J Cancer; 1998 May; 76(4):499-505. PubMed ID: 9590125
[TBL] [Abstract][Full Text] [Related]
14. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of long duration-low temperature whole body hyperthermia when combined with tumor necrosis factor and carboplatin in rats.
Sakaguchi Y; Makino M; Kaneko T; Stephens LC; Strebel FR; Danhauser LL; Jenkins GN; Bull JM
Cancer Res; 1994 Apr; 54(8):2223-7. PubMed ID: 8174130
[TBL] [Abstract][Full Text] [Related]
16. [Probability of the combination use of cisplatin and carboplatin].
Kobayashi K; Hino M; Hayashihara K; Niitani H
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2684-92. PubMed ID: 2277219
[TBL] [Abstract][Full Text] [Related]
17. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
[TBL] [Abstract][Full Text] [Related]
18. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
Ma GY; Bartlett DL; Reed E; Figg WD; Lush RM; Lee KB; Libutti SK; Alexander HR
Cancer J Sci Am; 1997; 3(3):174-9. PubMed ID: 9161783
[TBL] [Abstract][Full Text] [Related]
19. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
[TBL] [Abstract][Full Text] [Related]
20. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
